Telix Pharmaceuticals Limited has announced the publication of initial results from the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) in the European Journal of Nuclear Medicine and Molecular Imaging. The global registry aims to improve access to prostate cancer imaging, utilizing SPECT imaging technology, which is more widely available than PET/CT scanners. The study involved 40 patients across six countries, with 42.5% experiencing a change in management based on SPECT findings. No adverse events were reported. The findings indicate that technetium-based PSMA imaging could enhance global patient access to prostate cancer diagnostics. Telix and the Oncidium foundation plan further clinical activities for NOBLE to expand access for patients lacking access to current imaging technologies.
Mon, 30 Dec 2024 20:47:21 GMT | GlobeNewswire